BCIQ Profiles

Company Profile Report

Janssen takes another shot at off-the-shelf CAR Ts with Fate deal

Janssen is adding an off-the-shelf CAR-T and CAR-NK technology to build out its cancer cell therapy pipeline through a deal with Fate Therapeutics, marking at least the second time the company has partnered for allogeneic CAR T cells.

Fate Therapeutics

Read the full 391 word article

How to gain access

Continue reading with a
two-week free trial.